We are live on ! Find out more
BBH icon

VanEck Biotech ETF

115 hedge funds and large institutions have $147M invested in VanEck Biotech ETF in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 35 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

321% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $243K

0.2% more ownership

Funds ownership: 30.44%30.64% (+0.2%)

9% less funds holding

Funds holding: 126115 (-11)

14% less capital invested

Capital invested by funds: $171M → $147M (-$23.5M)

34% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 35

38% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 21

Holders
115
Holders Change
-11
Holders Change %
-8.73%
% of All Funds
1.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
23
Reduced
35
Closed
21
Calls
$1.02M
Puts
$243K
Net Calls
+$781K
Net Calls Change
+$2.1M

BBH Hedge Fund Activity: Q1 2022 in Review

115 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2022, worth a combined $147M — down 14% from $171M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of BBH and 13 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 23 added.

The largest buyer was Traphagen Investment Advisors, adding an estimated $8.97M. The largest seller was Bank of America, cutting an estimated $9.88M.

  • 115 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2022, down from 126 in Q4 2021.
  • Funds reported $147M of VanEck Biotech ETF stock for Q1 2022, down 14% quarter-over-quarter.
  • 13 funds opened new VanEck Biotech ETF positions in Q1 2022 and 21 closed out, a net change of -8 holders.
  • The largest VanEck Biotech ETF buyer in Q1 2022 was Traphagen Investment Advisors, an estimated $8.97M added.
  • The largest VanEck Biotech ETF seller in Q1 2022 was Bank of America, an estimated $9.88M sold.

Based on aggregated 13F filings for Q1 2022.